1-2 of 2
Marianne Tawa
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Combination of Duvelisib, a PI3K-δ,γ Inhibitor, and Romidepsin Is Highly Active in Relapsed/Refractory Peripheral T-Cell Lymphoma with Low Rates of Transaminitis: Results of Parallel Multicenter, Phase 1 Combination Studies with Expansion Cohorts

Steven M. Horwitz, MD, Alison J. Moskowitz, MD, Eric D Jacobsen, MD, Neha Mehta-Shah, MD, Michael S Khodadoust, MDPhD, David C. Fisher, MD PhD, Patricia Myskowski, MD, Erica B.K. Wang, MD, Marianne Tawa, RN, MSN, ANP, Theresa Davey, MMSc, PA-C, William Blouin, MBA, Helen Hancock, NP, Nivetha Ganesan, MPH, Natasha Galasso, BA, Evan Marzouk, BA, Alexandra Bahgat, BS, Hallie Jester, BA, Sophia Fong, BS, Abeer Butt, BS, Ahmet Dogan, MD PhD, Youn H. Kim, MD, David M Weinstock, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 683.
https://doi.org/10.1182/blood-2018-99-115241
Published: 2018
Journal Articles

Low-Dose Alemtuzumab Is Uniquely Effective in Refractory Leukemic Cutaneous T Cell Lymphoma (L-CTCL).

David C. Fisher, MD, Marianne Tawa, Michele Walsh, Nurse, Practioner, Rachael A Clark, MD, PhD, Thomas S. Kupper, MD
Journal: Blood
Blood (2009) 114 (22): 3748.
https://doi.org/10.1182/blood.V114.22.3748.3748
Published: 2009